Systemic inflammation response index and aggregate inflammation systemic index in male and female cancers: Implication for gender based immunotherapy

Abstract

<b>Background:</b> Several blood cell ratios have emerged as easy and minimally evasive inflammatory markers of cancer progression and management. Systemic inflammation response index (SIRI) and aggregate inflammation systemic index (AISI), which are reliable indicators of inflammation because they are calculated using more than two immune cells, have not been widely studied. The present study is particularly important in delineating gender-based cancers and to suggest inflammation based therapy.<br /> <b>Methods: </b>SIRI and AISI were calculated from differential white blood cell counts using automatic hematology analyzer in 50 cervical patients, 50 prostate cancer patients and 61 corresponding controls.<br /> <b>Results</b>: Mean values of SIRI and AISI were significantly raised in cervical cancer patients and prostate cancer patients compared with corresponding control. The mean white blood cell and neutrophil counts were significantly raised while SIRI, monocyte counts and AISI were significantly reduced in prostate cancer patients compared with cervical cancer patients.<br /> <b>Conclusions</b>: This study suggests that inflammation is a phenomenon in cervical- and prostate- cancer patients but the impact of inflammation might be more in cervical cancer patients, suggesting that sex hormones might limit the efficacy of broad spectrum single cancer immunotherapy for both sexes.